Lisuride
This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Lisuride".

Lisuride
Systematic (IUPAC) name
1,1-diethyl-3-((6aR,9S)-7-methyl- -4,6,6a,7,8,9-hexahydroindolo[4,3-fgquinolin-9-yl)urea
Identifiers
CAS number	18016-80-3
ATC code	G02CB02 N02CA07
PubChem	28864
DrugBank	APRD00636
Chemical data
Formula	C20H26N4O
Mol. mass	338.447 g/mol
Pharmacokinetic data
Bioavailability	10-20% for lisuride hydrogenmaleate
Protein binding	about 15%
Metabolism	Hepatic
Half life	2 hours
Excretion	renal and biliary in equal amounts
Therapeutic considerations
Pregnancy cat.	?
Legal status	Prescription only
Routes	Oral, subcutaneous, transdermal

Lisuride (brand name in Germany Dopergin) is an anti-Parkinson's drug of the iso-ergoline class, chemically related to the dopaminergic ergoline Parkinson's drugs. Lisuride is described as free base (see table on the right) and as hydrogenmaleate salt.

Lisuride is used to lower prolactin and, in low doses, to prevent migraine attacks. The use of lisuride as initial anti-Parkinsonian treatment has been advocated, delaying the need for levodopa until lisuride becomes insufficient for controlling the Parkinsonian disability. Preliminary trials suggest that the dermal application of lisuride may be useful in the treatment of Parkinson's disease. Lisuride is not currently available in the US.

Mode of action

Lisuride is a dopamine agonist.

Commercial names

History

Synthesis of lisuride was first described in 1960.

Indications

• Parkinson's Disease

See also

• Dopamine receptor